학술논문

Human tau mutations in cerebral organoids induce a progressive dyshomeostasis of cholesterol
Document Type
article
Source
Stem Cell Reports. 17(9)
Subject
Biochemistry and Cell Biology
Bioinformatics and Computational Biology
Genetics
Biological Sciences
Acquired Cognitive Impairment
Alzheimer's Disease
Neurosciences
Neurodegenerative
Frontotemporal Dementia (FTD)
Dementia
Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD)
Rare Diseases
Aging
Brain Disorders
2.1 Biological and endogenous factors
Aetiology
Neurological
Cholesterol
Frontotemporal Dementia
Humans
Mutation
Organoids
tau Proteins
MAPT mutation
astrocyte
brain organoid
cholesterol
disease model
neurodegeneration
single-cell RNA sequencing
tau
tauopathy
Clinical Sciences
Biochemistry and cell biology
Language
Abstract
Mutations in the MAPT gene that encodes tau lead to frontotemporal dementia (FTD) with pathology evident in both cerebral neurons and glia. Human cerebral organoids (hCOs) from individuals harboring pathogenic tau mutations can reveal the earliest downstream effects on molecular pathways within a developmental context, generating interacting neurons and glia. We found that in hCOs carrying the V337M and R406W tau mutations, the cholesterol biosynthesis pathway in astrocytes was the top upregulated gene set compared with isogenic controls by single-cell RNA sequencing (scRNA-seq). The 15 upregulated genes included HMGCR, ACAT2, STARD4, LDLR, and SREBF2. This result was confirmed in a homozygous R406W mutant cell line by immunostaining and sterol measurements. Cholesterol abundance in the brain is tightly regulated by efflux and cholesterol biosynthetic enzyme levels in astrocytes, and dysregulation can cause aberrant phosphorylation of tau. Our findings suggest that cholesterol dyshomeostasis is an early event in the etiology of neurodegeneration caused by tau mutations.